COVID-19 linked to cardiac injury, worse outcomes for patients with heart conditions
COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying heart conditions.
Experts have known that viral illnesses such as COVID-19 can cause respiratory infections that may lead to lung damage and even death in severe cases. Less is known about the effects on the cardiovascular system.
According to experts at The University of Texas Health Science Center at Houston ( UTHealth ), it is likely that even in the absence of previous heart disease, the heart muscle can be affected by coronavirus disease. Overall, injury to heart muscle can happen in any patient with or without heart disease, but the risk is higher in those who already have heart disease.
Research from previous coronavirus and influenza epidemics suggest that viral infections can cause acute coronary syndromes, arrhythmias, and the development of, or exacerbation of, heart failure.
In a clinical bulletin issued by the American College of Cardiology, it was revealed that the case fatality rate of COVID-19 for patients with cardiovascular disease was 10.5%.
Data also points to a greater likelihood that individuals over the age of 65 with coronary heart disease or hypertension can contract the illness, as well experience more severe symptoms that will require critical care.
According to the study authors, critical cases are those that reported respiratory failure, septic shock, and/or multiple organ dysfunction or failure that resulted in death.
It is reasonable to expect that significant cardiovascular complications linked to COVID-19 will occur in severe symptomatic patients because of the high inflammatory response associated with this illness.
The novel virus that causes COVID-19 was first identified in January 2020. This novel virus originated in Wuhan, China, and by March 11, 2020, the World Health Organization ( WHO ) had declared it a global pandemic.
The three most common symptoms of COVID-19 include fever, cough, and shortness of breath. Other less common symptoms are muscle pain, sore throat, nasal congestion, and headache.
Symptoms can appear as soon as two days after exposure to the virus to up to14 days after.
There is a high viral load in both symptomatic and asymptomatic patients, meaning asymptomatic spread between person to person is likely.
Previously identified coronaviruses known to cause severe illness in humans include Severe Acute Respiratory Syndrome Coronavirus ( SARS-CoV ) and Middle East Respiratory Syndrome ( MERS-CoV ).
SARS-CoV was first identified in southern China in 2002, and by 2003 it had killed over 8,000 individuals in 29 countries. Data suggests that SARS-CoV may have resulted in cardiovascular complications, such as acute coronary syndrome and myocardial infarction.
MERS-CoV was first discovered in 2012 in Saudi Arabia. As of 2019, 2,494 cases have been confirmed along with 858 deaths in 26 countries.
Current COVID-19 treatment options are being researched, and there is a large effort to develop vaccines for prevention and to test antivirals for the treatment of the disease.
In the meantime, the study authors encourage all individuals to consult with their health care providers about being vaccinated against influenza and that at-risk patients seek advice on receiving a pneumonia vaccine from their primary care physician. While these vaccines will not provide specific protection against COVID-19, they can help prevent superimposed infections alongside COVID-19. ( Xagena )
Source: JAMA Cardiology, 2020
The FDA ( US Food and Drug Administration ) has approved the following expanded indication for Entresto ( Sacubitril /...
The FDA ( U.S. Food and Drug Administration ) has approved Darzalex Faspro ( Daratumumab and Hyaluronidase-fihj ), a...
Real-world ACS population: Ticagrelor doesn’t lessen risks of myocardial infarction or death and may increase bleeding relative to Clopidogrel
Major bleeding after acute coronary syndrome predicts a poor outcome but is challenging to define. The choice of antiplatelet influences...
hATTR amyloidosis with polyneuropathy: Vutrisiran has improved progression of neuropathy, quality of life, and gait speed
HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated ( ATTR )...
HELIOS-A study: Vutrisiran has reversed polyneuropathy manifestations with improvements in neuropathy, quality of life, and gait speed
Full positive results from the HELIOS-A phase 3 study of Vutrisiran, an investigational RNAi therapeutic in development for the treatment...
Farxiga for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes, approved by FDA
Farxiga ( Dapagliflozin ), a sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor, has been approved in the US to reduce...
Verquvo, a symptomatic chronic heart failure treatment in adult patients with reduced ejection fraction
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...
EMA’s human medicines committee ( CHMP ) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty (...
Myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults
Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination...
Kerendia for the treatment of patients with chronic kidney disease associated with type 2 diabetes - FDA approved
The FDA ( U.S. Food and Drug Administration ) has approved Kerendia ( Finerenone ), the first non-steroidal, selective mineralocorticoid...